Exhibit 99.1

 ASX Market Announcement Results of General Meeting In accordance with ASX Listing Rule 3.13.2 & section 251AA of the Corporations Act, the following information is provided to the ASX in relation to the resolutions passed by the shareholders of Genetic Technologies Limited (‘Company’), at its General Meeting of shareholders held on 26 September 2019. All resolutions put to the meeting were passed on a show of hands. The Company received 199,902,693 valid proxy votes in respect of each resolution. The Chairman voted all undirected proxies held at his discretion in favour of each resolution. The instructions given to validly appointed proxies in respect of the resolutions were as follows: Justyn Stedwell Company Secretary About Genetic Technologies Limited Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. GTG offers cancer predictive testing and assessment tools to help physicians proactively manage patient health. The Company’s lead products GeneType for Breast Cancer for non-hereditary breast cancer and GeneType for Colorectal Cancer are clinically validated risk assessment tests and are first in class. Genetic Technologies is developing a pipeline of risk assessment products. For more information, please visit www.gtglabs.com Genetic Technologies Limited60-66 Hanover Street www.gtglabs.comFitzroy Victoria 3065 info@gtglabs.comAustralia ABN 17 009 212 328+61 3 8412 7000 Resolution For Against Abstain Chairman's Discretion Excluded 1. Ratify 24/10/18 Share Issue 84,240,870 10,180,216 1,415,408 4,064,993 100,001,206 2. Ratify 6/05/19 Share Issue 80,697,064 13,248,616 1,890,814 4,064,993 100,001,206 3. Ratify 23/05/19 Securities Issue 180,848,676 13,248,616 1,630,408 4,174,993 0 4. Ratify 23/05/19 Securities Issue 181,055,936 13,248,616 1,533,148 4,064,993 0 5. Approve proposed placement 176,569,764 17,529,619 1,738,317 4,064,993 0